MagForce AG, DE000A0HGQF5

MagForce AG, DE000A0HGQF5

12.04.2017 - 09:03:51

MagForce AG participates in six upcoming international conferences in Q2 2017

MagForce AG participates in six upcoming international conferences in Q2 2017

Berlin, Germany and Nevada, USA, April 12, 2017 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in six upcoming scientific and investor conferences in the second quarter 2017:

5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) Date: May 04-07, 2017 Location: Zurich, Switzerland Lunch Symposium: "Focal Therapy in Glioblastoma - Current Status I What's New?!" Saturday, May 06, 2017, 12:15-13:15 CEST   8th DVFA Spring Conference 2017 Date: May 08-10, 2017 Location: Frankfurt am Main, Germany Presentation: Ben J. Lipps, CEO of MagForce AG, Wednesday, May 10, 2017   Goldman Sachs European Small & Mid-Cap Symposium Date: May 11, 2017 Location: London, United Kingdom Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, May 11, 2017   Berenberg European Conference USA 2017 Date: May 22-24, 2017 Location: Tarrytown, New York, USA Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, May 23, 2017   Deutsche Bank 20th Annual dbAccess German, Swiss & Austrian Conference Date: June 21-23, 2017 Location: Berlin, Germany Presentation: Ben J. Lipps, CEO of MagForce AG, Wednesday, June 21, 2017   Long Night of the Sciences (Lange Nacht der Wissenschaften) Date: June 24, 2017 Location: Berlin and Potsdam, Germany

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the new Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact: Barbara von Frankenberg Vice President Communications & Investor Relations T +49-30-308380-77 E-Mail: bfrankenberg@magforce.com

12.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: MagForce AG Max-Planck-Straße 3 12489 Berlin

Germany Phone: +49 (0)30 308 380 0 Fax: +49 (0)30 308 380 99 E-mail: info@magforce.com Internet: www.magforce.com ISIN: DE000A0HGQF5 WKN: A0HGQF Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart, Tradegate Exchange; Open Market (Scale) in Frankfurt   End of News DGAP News Service

564321  12.04.2017 

@ dgap.de

Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!